Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders

Ferracioli-Oda, Eduardo; Qawasmi, Ahmad; Bloch, Michael H.

doi:10.1176/appi.focus.12.1.73

Cited by 39 publications

(45 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Melatonin has been used for improving sleep in patients with insomnia mainly because it does not cause hangover or show any addictive potential. Melatonin's efficacy has been demonstrated in most [182,183] but not all meta-analysis [184]. Brain imaging studies in awake subjects have revealed that melatonin modulates brain activity pattern to one resembling that of actual sleep [185].…”

Section: Levels Of Amt6s In 12-h Overnight Urine Samplesmentioning

confidence: 99%

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Cardinali¹,

Escames²,

Acuña-Castroviejo³

et al. 2016

J Integr Oncol

View full text Add to dashboard Cite

Section: Levels Of Amt6s In 12-h Overnight Urine Samplesmentioning

confidence: 99%

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Cardinali¹,

Escames²,

Acuña-Castroviejo³

et al. 2016

J Integr Oncol

View full text Add to dashboard Cite

“…This result has been reproduced in the meta-analysis by Ferracioli-Oda, et al [9] Based on the current inclusion of melatonin in the management of RBD, it is hoped in future there will be an increase in robust evidence for its widespread use. Participants unsuitable (n= 5) [26][27][28][29][30] Insufficient data for analysis (n= 2) [31,32] Inappropriate method and data collection (n= 4) [33][34][35][36] No clear comparison group (n= 4) [37][38][39][40] Number of studies included in review (n=13) [41][42][43][44][45][46][47][48][49][50][51][52] Publications handpicked (screening reference list) (n= 2) …”

mentioning

confidence: 65%

“…[2,3] Previous studies have highlighted the potential use of melatonin in treating primary and secondary [4] sleep disorders in adults [5,6,7] and others have indicated melatonin can decrease sleep onset latency and increase the total time asleep, thus improving sleep quality overall. [8] Ferracioli-Oda et al [9] verified using melatonin in adults with primary sleep disorders improves sleep parameters (i.e., a higher dose has a greater effect on sleep latency and total sleep time).…”

Section: Melatonin Use In Sleep Disordersmentioning

confidence: 99%

Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders

Auld

Maschauer

Morrison

et al. 2017

Sleep Medicine Reviews

311

137

View full text Add to dashboard Cite

Melatonin is a physiological hormone involved in sleep timing and is currently used exogenously in the treatment of primary and secondary sleep disorders with empirical evidence of efficacy, but very little evidence from randomised, controlled studies. The aim of this meta-analysis was to assess the evidence base for the therapeutic effects of exogenous melatonin in treating primary sleep disorders. An electronic literature review search of MEDLINE (1950-present) EMBASE (1980- present), PsycINFO (1987- present), and SCOPUS (1990- present), along with a hand-searching of key journals was performed in July 2013 and then again in May 2015. This identified all studies that compared the effect of exogenous melatonin and placebo in patients with primary insomnia, delayed sleep phase syndrome, Non 24- hour sleep wake syndrome in people who are blind, and REM-Behaviour Disorder. Meta-analyses were performed to determine the effect of magnitude in studies of melatonin in improving sleep. A total of 5030 studies were identified; of these citations, 13 were included for review based on the inclusion criteria of being: double or single-blind, randomised and controlled. Results from the meta-analyses showed the most convincing evidence for exogenous melatonin use was in reducing sleep onset latency in primary insomnia (p=0.002), delayed sleep phase syndrome (p<0.0001), and regulating the sleepwake patterns in blind patients compared with placebo. These findings highlight the potential importance of melatonin in treating certain first degree sleep disorders. The development of large-scale, randomised, controlled trials is recommended to provide further evidence for therapeutic use of melatonin in a variety of sleep difficulties

show abstract

“…In all patients, an AHI of less than 5/h was achieved. The CPAP treatment also resulted in a reduction in daytime sleepiness (median [IQR] ESS score, 13 [8][9][10][11][12][13][14][15][16][17][18][19][20] Baseline serum melatonin concentrations In the majority of the study population, the highest serum melatonin levels were noted at 2 AM (FIGURE 2). This finding was reported for all controls and for 53 of the 71 patients (74.6%) with OSA.…”

Section: Methodsmentioning

confidence: 99%

Treatment with continuous positive airway pressure and diurnal and nocturnal serum melatonin concentration in patients with obstructive sleep apnea

Barnaś¹,

Maskey-Warzęchowska²,

Bielicki³

et al. 2017

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

ORIGINAL ARTICLE CPAP treatment and serum melatonin in OSA 589 models and humans have shown that melatonin secretion is strongly related to sleep, and individuals with decreased melatonin levels suffer from sleep disturbances and insomnia. This refers to elderly patients (as melatonin concentrations tend to fall with age), night-shift workers with an exogenously disrupted sleep-wake rhythm, individuals who had undergone pinealectomy, and others.1,2,10 In patients with primary insomnia, exogenous melatonin decreases sleep onset latency, increases total sleep time, and improves sleep quality. 11,12 Melatonin also effectively reduces jet INTRODUCTION Melatonin is a serotonin-derived hormone secreted by the pineal gland in a cyclic manner. 1 It has diverse activities and regulates numerous physiological processes in mammals, including the sleep-wake rhythm, sexual maturation, reproduction, and aging. It also has antioxidant, oncostatic, and immunomodulative properties.1-3 Its release responds to the light-dark cycle.4-6 The peak melatonin secretion occurs during the night hours; during the day, its concentrations are low. Exposure to light acutely suppresses nocturnal melatonin release. OBJECTIVES The aim of the study was to evaluate the profile of circadian melatonin secretion in patients with obstructive sleep apnea (OSA) and to assess the impact of 2-day and 3-month treatment with continuous airway pressure (CPAP) on diurnal and nocturnal serum melatonin levels.PATIENTS AND METHODS Serum melatonin levels were evaluated in 71 untreated patients with OSA and 18 healthy controls at 6 time points: 10 AM, 2 PM, 6 PM, 10 PM, 2 AM, and 6 AM. The measurements were repeated after 2 days and 3 months of CPAP treatment. RESULTSMelatonin secretion rhythm was altered in 25.4% of the patients with OSA. In patients with preserved secretion rhythm, the serum melatonin level was significantly lower at 2 AM and 6 AM, compared with healthy controls: 68.2 pg/ml (interquartile range [IQR], 30.1-109.8 pg/ml) vs 109.1 pg/ml (IQR, 63-167.9 pg/ml), P = 0.02 and 40.8 pg/ml (IQR,.2 pg/ml) vs 67.7 pg/ml (IQR, 32.7-131.7 pg/ml), P = 0.04, respectively. Melatonin levels did not change significantly after the 2-day and 3-month CPAP treatment. However, at 3 months, a shift of the peak melatonin concentration to 2 AM was observed in patients with an altered secretion rhythm.CONCLUSIONS OSA has a significant effect on serum melatonin levels. Neither short-term nor long-term CPAP treatment significantly changes melatonin concentrations; however, our results seem to indicate that a 3-month CPAP treatment may be helpful in restoring the physiological rhythm of melatonin secretion in patients with OSA.

show abstract

Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders

Cited by 39 publications

References 12 publications

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Melatonin-Induced Oncostasis, Mechanisms and Clinical Relevance

Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders

Treatment with continuous positive airway pressure and diurnal and nocturnal serum melatonin concentration in patients with obstructive sleep apnea

Contact Info

Product

Resources

About